Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$57.8M
- Net margin
- —
Little or no net debt.
- Total debt
- $0
- Cash
- $28.7M
- Debt / equity
- 0.00
Comfortably covers what is due within a year.
- Current assets
- $28.8M
- Current liabilities
- $5.1M
- Current ratio
- 5.63
Consumes cash and must keep raising it.
- Operating cash flow
- -$11.1M
- Free cash flow
- -$11.1M
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 4.6M
- Share growth (1y)
- 987.7%
- Cash runway
- 31 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
ADIL Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 5.40 M | 1.57 M | 1.27 M | 1.24 M | 1.15 M | 1.52 M |
| R&D Expense | 440.00 K | 432.53 K | 619.40 K | 521.07 K | 732.32 K | 746.89 K |
| Operating Expenses | 52.02 M | 2.00 M | 1.89 M | 1.76 M | 1.88 M | 2.27 M |
| Operating Income | -52.02 M | -2.00 M | -1.89 M | -1.76 M | -1.88 M | -2.27 M |
| Pretax Income | -51.99 M | -2.02 M | -2.00 M | -1.79 M | -1.96 M | -2.23 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -51.99 M | -2.02 M | -2.00 M | -1.79 M | -1.96 M | -2.23 M |
| EPS (Basic) | -11.25 | -1.48 | -1.80 | -2.00 | -4.50 | -8.50 |
| EPS (Diluted) | -11.25 | -1.48 | -1.80 | -2.00 | -4.50 | -8.50 |
| Shares Outstanding | 4.62 M | 1.37 M | 1.11 M | 886.85 K | 424.91 K | 743.55 K |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.